BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36595771)

  • 1. Geriatric nutritional risk index as a prognostic factor in patients with hepatocellular carcinoma following transarterial chemoembolization: A retrospective study.
    Si Y; Xu P; Xu A; Wang P; Zhao K
    Medicine (Baltimore); 2022 Dec; 101(51):e32322. PubMed ID: 36595771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W
    Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
    Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
    World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Nomogram for Hepatitis B Virus-related Hepatocellular Carcinoma With Adjuvant Transarterial Chemoembolization After Radical Resection.
    Huang J; Liu FC; Li L; Yuan SX; Yang Y; Jiang BG; Liu H; Pan ZY
    Am J Clin Oncol; 2020 Jan; 43(1):20-27. PubMed ID: 31633514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
    Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
    World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
    Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
    Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
    J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study.
    Hsu CY; Liu PH; Hsia CY; Lee YH; Nagaria TS; Lee RC; Lin HC; Huo TI
    Ann Surg Oncol; 2016 Mar; 23(3):994-1002. PubMed ID: 26487000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
    Niu XK; He XF
    World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Geriatric Nutritional Risk Index After Initial Hepatectomy for Hepatocellular Carcinoma: a Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO).
    Imaoka Y; Ohira M; Kobayashi T; Honmyo N; Hamaoka M; Onoe T; Abe T; Oishi K; Inoue M; Ohdan H;
    J Gastrointest Surg; 2023 Jun; 27(6):1152-1158. PubMed ID: 36869207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis.
    Risaliti M; Bartolini I; Campani C; Arena U; Xodo C; Adotti V; Rosi M; Taddei A; Muiesan P; Amedei A; Batignani G; Marra F
    World J Gastroenterol; 2022 Aug; 28(29):3981-3993. PubMed ID: 36157535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
    Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
    BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
    Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Adjuvant Transarterial Chemoembolization after Radical Hepatectomy in Solitary Hepatocellular Carcinoma Patients: A Retrospective Study.
    Zeng G; Zou B; Li Y; Lin E; Liu X; Li P; Chen J; Zhang B; Jia Y; Cai C; Li J
    J Invest Surg; 2022 Jun; 35(6):1208-1216. PubMed ID: 35078386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.